Kopran Limited stock analysis

The increasing contribution from CDMO/CMO operations is anticipated to enhance the Company’s margin profile through higher-value offerings while providing greater revenue visibility and a more stable, recurring business stream pg. 02-19 Going forward, the Company is aligning its formulation development strategy with its API portfolio to increase backward integration and leverage its in-house manufacturing capabilitie

India currently exports pharmaceutical products to more than 190 countries, with regulated markets such as the U.S. and Europe continuing to account for a significant share of exports.17 Active Pharmaceutical Ingredient (API) Industry India’s pharmaceutical exports crossed approximately $30 billion in FY 2025-26, with APIs and drug intermediates continuing to contribute significantly to export growth.19 India also su

The industry is also witnessing higher localisation of key starting materials (KSMs) and intermediates, helping reduce import dependence for critical drug manufacturing. Under the government’s PLI initiatives, investments in API and bulk drug manufacturing have already crossed earlier targets, while new greenfield projects and bulk drug parks are improving utility access, logistics efficiency, and production economic

Opportunities from Backward Integration and Intermediates The Company continues to focus on Advanced Intermediates, localisation initiatives and process optimisation to reduce raw material dependence and improve operational flexibility. Expansion of the Panoli API and R&D facility, along with development of intermediates for key APIs, is expected to support cost optimisation and margin improvement over the medium ter

The Company has also set up a brownfield API manufacturing facility in Panoli, Gujarat. 35 Management Discussion and Analysis (Contd..) The Company’s Panoli manufacturing facility commenced commercial production on 31 March 2026. Following the commencement of operations, the Company is actively pursuing the necessary regulatory approvals and customer qualifications across various domestic and international markets.

Increasing focus on high-potency APIs, peptide-based therapeutics, oncology APIs and CDMO partnerships is further improving the industry’s value mix and export competitiveness. Rising regulatory approvals, quality-compliance investments and digital manufacturing adoption are also expected to support long-term growth across the sector. Outlook India’s API sector is entering a new phase of growth during FY 2025–26, sup

Diversification strengthens our ability to expand our portfolio, access new opportunities and build resilient growth platforms. Our focus on specialised products, global partnerships and market expansion positions us to address evolving healthcare needs. As we move forward, we remain committed to advancing with purpose, agility and excellence.